A Study of Brequinar in Subjects With Relapsed/Refractory Acute Myeloid Leukemia

Протокол NCT03760666
Описание
Статус выполнения
completedResults
Ход выполнения
100%
20.12.2018
09.02.2021
Цели
A Phase 1b/2a multi-center, open-label, non-randomized study to assess the safety, tolerability and efficacy of dose-adjusted brequinar in adult subjects with acute myeloid leukemia (AML). Ribavirin BID may be added to brequinar twice weekly in eligible subjects.
Организация, проводящая КИ
Clear Creek Bio, Inc.
Фаза КИ
II
Количество пациентов
17

Новости и обновления